BioLineRx Ltd. (BLRX) Releases Earnings Results, Meets Estimates
BioLineRx Ltd. (NASDAQ:BLRX) issued its earnings results on Tuesday. The biotechnology company reported ($0.05) EPS for the quarter, hitting analysts’ consensus estimates of ($0.05), MarketWatch Earnings reports.
Shares of BioLineRx (NASDAQ BLRX) traded up 2.63% during midday trading on Tuesday, reaching $1.17. 421,397 shares of the company were exchanged. The stock’s 50-day moving average price is $0.90 and its 200-day moving average price is $0.96. The company’s market capitalization is $72.28 million. BioLineRx has a 52-week low of $0.75 and a 52-week high of $1.42.
COPYRIGHT VIOLATION NOTICE: This story was published by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/08/08/biolinerx-ltd-blrx-releases-earnings-results-meets-estimates.html.
A number of equities analysts recently commented on the stock. Oppenheimer Holdings, Inc. assumed coverage on shares of BioLineRx in a research note on Friday. They set an “outperform” rating and a $3.00 target price for the company. Roth Capital assumed coverage on shares of BioLineRx in a research note on Thursday, August 3rd. They set a “buy” rating and a $3.00 target price for the company. Zacks Investment Research upgraded shares of BioLineRx from a “sell” rating to a “hold” rating in a research note on Wednesday, July 26th. ValuEngine upgraded shares of BioLineRx from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. Finally, Maxim Group set a $3.00 target price on shares of BioLineRx and gave the stock a “buy” rating in a research note on Monday, July 10th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. BioLineRx has an average rating of “Buy” and an average target price of $2.59.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Sabby Management LLC bought a new position in shares of BioLineRx during the first quarter valued at $3,018,000. KCG Holdings Inc. raised its position in shares of BioLineRx by 715.9% in the first quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock valued at $168,000 after buying an additional 153,687 shares in the last quarter. Renaissance Technologies LLC bought a new position in shares of BioLineRx during the first quarter valued at $126,000. Citadel Advisors LLC raised its position in shares of BioLineRx by 443.4% in the first quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 86,481 shares in the last quarter. Finally, Benchmark Capital Advisors raised its position in shares of BioLineRx by 227.3% in the first quarter. Benchmark Capital Advisors now owns 144,000 shares of the biotechnology company’s stock valued at $138,000 after buying an additional 100,000 shares in the last quarter. 34.91% of the stock is owned by institutional investors.
BioLineRx Company Profile
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.